Contineum Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 3, 2026, covering the period ended September 30, 2026.

Key Highlights

  • Share count: As of October 30, 2026, the registrant had 39,265,813 total shares outstanding.
  • Class A common stock: 35,353,313 shares of Class A common stock, $0.001 par value per share, outstanding as of October 30, 2026.
  • Class B common stock: 3,912,500 shares of Class B common stock, $0.001 par value per share, outstanding as of October 30, 2026.
  • Company status: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Lead drug candidate: The filing identifies PIPE-791 as the company's lead drug candidate, described as being in early stages of clinical development.
  • Licensing relationship: The filing references Janssen Pharmaceutica NV, a Johnson & Johnson company, in connection with plans related to the clinical development of PIPE-307.

Contineum Therapeutics Discloses Pipeline Status and Capital Structure in September 2026 Quarterly Filing

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a Delaware-incorporated biopharmaceutical company headquartered at 3565 General Atomics Court, Suite 200, San Diego, California 92121, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing was made under Commission File Number 001-42001. As of October 30, 2026, the company reported 39,265,813 total shares outstanding, comprised of 35,353,313 shares of Class A common stock and 3,912,500 shares of Class B common stock, each with a par value of $0.001 per share.

According to the filing, the company's lead drug candidate is PIPE-791, which the registrant described as being "in the early stages of clinical development." The filing also references PIPE-307, noting that Janssen Pharmaceutica NV, a Johnson & Johnson company, holds plans related to its clinical development. The registrant stated that it is "heavily dependent on the success of PIPE-791" and that failure of PIPE-791, PIPE-307, or other drug candidates to progress through clinical development, receive regulatory approval, or achieve successful commercialization would "materially adversely harm" its business.

The filing contains forward-looking statements regarding clinical trial timelines, regulatory filings, capital requirements, and operating runway, among other topics. The registrant noted that such statements involve "known and unknown risks, uncertainties and other important factors" and that actual results may differ materially. The company stated it assumes no obligation to update or revise forward-looking statements except as required by law. The registrant confirmed it has filed all required Exchange Act reports during the preceding 12 months and has submitted all required Interactive Data Files electronically.

What Was Disclosed

Contineum Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing a total share count of 39,265,813 as of October 30, 2026, its dual-class capital structure, its dependence on lead candidate PIPE-791, and a third-party development relationship involving PIPE-307 with Janssen Pharmaceutica NV.